Mevion Announces First Clinical Treatment on the MEVION S250-FIT™ Proton Therapy System Mevion Medical Systems, a global leader in compact proton therapy, announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has…
Sasol Advances Strategic Growth in Advanced Materials and Specialty Chemicals with €60 Million Brunsbüttel Investment Sasol International Chemicals announced a €60 million investment at its Brunsbüttel site to expand its advanced materials and specialty chemicals capabilities, reinforcing the company’s position…
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that the first patient has been dosed…
CitroTech Expands Patent Portfolio, Leading the Market for GPS-Verified, AI-Enabled Deployment of Eco-Friendly Fire Retardants CitroTech announced the continued expansion of its intellectual property (IP) portfolio, reinforcing its position as the only company in wildfire prevention whose platform combines GPS-enabled…
Pittsburgh Paints Co. Introduces PITTSBURGH PAINTS Protective Coatings The Pittsburgh Paints Company launched the PITTSBURGH PAINTS™ Protective Coatings brand, the new face of PPG HIGH PERFORMANCE COATINGS™. In addition to the new brand’s offerings of industry-leading, full-system solutions, trusted products…
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy…
Wiley Acquires Emerald, Expanding Research Scale and Deepening Proprietary Content Across the AI-Driven Knowledge Economy Wiley a global leader in authoritative content and research intelligence, announced it has acquired Emerald Publishing Limited (“Emerald”) from Cambridge Information Group (CIG) in an…
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At…
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Rallybio Corporation and Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive…
Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer Qurient Co., Ltd. announced that the first patient has been dosed in a Phase 2 clinical study evaluating…
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Merck known as MSD outside of the United States and Canada, announced that…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…